The FDA approved the travoprost intracameral implant (iDose TR) for treatment of ocular hypertension and glaucoma, device developer Glaukos announced on Thursday. The implant is designed to provide ...

New first-line laser treatment for the nearly 5 million Americans diagnosed with glaucoma1,2 Automated device enables a streamlined workflow without a gonio lens or manual aiming2 Voyager Direct ...

Please provide your email address to receive an email when new articles are posted on . One-fifth of patients who received ocular steroid injections were later diagnosed with glaucoma or ocular ...

Omlonti is a relatively selective EP2 receptor agonist designed to increase aqueous humor drainage through the conventional (or trabecular) and uveoscleral outflow pathways. The Food and Drug ...

Between February 1994 and October 1996, 3,328 individuals were considered for the study enrollment and 1,636 individuals met the requirements for the study. Recruitment was extended from 24 months to ...

In matched cohorts of more than 41,000 patients each, use of tirzepatide was linked to a significantly reduced risk of ...

CHICAGO -- Upfront laser trabeculoplasty significantly slowed glaucoma progression and vision loss as compared with eye drops, long-term follow-up from a large randomized trial showed. After 6 years ...

High eye pressure does not always cause glaucoma, but it is a significant risk factor. Lowering high eye pressure may reduce the risk, although glaucoma can also occur in people with typical eye ...

GENEVA--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care, dedicated to helping people see brilliantly, announced today the full U.S. commercial availability of Voyager ™ DSLT, the ...